
... BIBLIOGRAPHY ...

- American Heart Association. *Heart and Stroke Facts: 1996 Statistical Supplement* Dallas, TX: American Heart Association; 1996:1.
- Andrade SE, Walker AM, Gottlieb LK, et al. Discontinuation of antihyperlipidemic drugs: Do rates reported in clinical trials reflect rates in primary care settings? *N Engl J Med* 1995;332:1125-1131.
- Antiplatelet Trialists' Collaboration. Secondary prevention of vascular disease by prolonged antiplatelet treatment. *BMJ* 1988;296:320-331.
- Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy, I. Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. *BMJ* 1994;308:81-106, 159-163, 235-246.
- Barrett-O'Connor E, Bush T. Estrogen and coronary heart disease in women. *JAMA* 1991;265:1861-1867.
- Brown B, Zhao X, Sacco D, Albers J. Lipid lowering and plaque regression: New insights into prevention of plaque disruption and clinical events in coronary disease. *Circulation* 1993;87:1781-1791.
- Cameron A, Davis K, Rogers W. Recurrence of angina after coronary artery bypass surgery: Predictors and prognosis (CASS Registry). *J Am Coll Cardiol* 1995;26:895-899.
- Centers for Disease Control and Prevention. Cigarette smoking-attributable mortality and years of potential life lost United States, 1990. *Morb Mortal Wkly Rep* 1993; 42:645-649.
- Cohen MV, Byrne M, Levine B, Gutowski T, Adelson R. Low rate of treatment of hypercholesterolemia by cardiologists in patients with suspected and proven coronary artery disease. *Circulation* 1991;83:1294-1304.
- Debusk RF, Houston-Miller N, Superko R, et al. A case-management system for coronary risk factor modification after acute myocardial infarction. *Ann Intern Med* 1994; 120:721-729.
- Ellerbeck EF, Jencks SF, Radford MJ, et al. Quality of care for Medicare patients with acute myocardial infarction: Four-State pilot study from the Cooperative Cardiovascular Project. *JAMA* 1995;273:1509-1514.
- Falk E, Shah PK, Fuster V. Coronary plaque disruption. *Circulation* 1995;92:657-671.
- Fuster V. Mechanisms leading to myocardial infarction: Insights from studies of vascular biology. *Circulation* 1994;90:2126-2146.
- Gillum RF, Neutra RR, Stason WB, Solomon HS. Determinants of dropout rate among hypertensive patients in an urban clinic. *J Community Health* 1979;5:94-100.
- Goldstein RE, Andrews M, Hall WJ, Moss AJ. Marked reduction in long-term cardiac deaths with aspirin after a coronary event. *J Am Coll Cardiology* 1996;28:326-330.
- Gotto AM. Lipid lowering, regression and coronary events. A review of the interdisciplinary council on lipids and cardiovascular risk-intervention, 7th council meeting. *Circulation* 1995;92:646-656.
- Gould AL, Roussouw JE, Santanello NC, Heyse JF, Furberg CD. Cholesterol reduction yields clinical benefit: A new look at old data. *Circulation* 1995;91:2274-2282.
- Grover SA, Coupal L, Hu XP. Identifying adults at increased risk of coronary disease: How well do the current cholesterol guidelines work? *JAMA* 1995;274:801-806.
- Grundy SM, Chait A, Clark LT, et al, for the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Summary of the second report of the National Cholesterol Education Program (NCEP). *JAMA* 1993;269:3015-3023.
- ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomized trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction. *Lancet* 1988;2:349-360.
- Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. The Fifth Report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure (JNC-V). *Arch Intern Med* 1993;153:154.
- Katzel L, Bleecker E, Colman E, et al. Effects of weight loss vs. aerobic exercise training on risk factors for coronary disease in healthy, obese, middle-aged and older men. *JAMA* 1995; 274:1915-1921.
- LaRosa JC. Cholesterol agonistics. *Ann Intern Med* 1996; 124:505-508.
- Lipid Research Clinics Program. The Lipid Research Clinics Coronary Primary Prevention (LRC-CPT) Trial results II: The relationship of reduction in incidence of coronary heart disease to cholesterol lowering *JAMA* 1984;251: 365-374.

- Malloy M. Effects of exercise on coronary atherosclerotic lesions. *J Am Coll Cardiol* 1993;22:468.
- Nieto FJ, Alonso J, Chambless LE, et al. Population awareness and control of hypertension and hypercholesterolemia. *Arch Intern Med*. 1995;155:677-684.
- Oettgen P, Ginsburg GS, Horowitz GL, Pasternak RC. Frequency of hypothyroidism in adults with serum total cholesterol levels 200 mg/dL. *Am J Card* 1994;73:955-957.
- Oldridge N, Guyatt G, Fischer M, Rimm A. Cardiac rehabilitation after myocardial infarction: Combined experience of randomized clinical trials. *JAMA* 1988;260:945-950.
- Pearson T, Criqui M, Luepker R, Oberman A, Winston M, eds. *Primer in Preventive Cardiology* Dallas, TX: American Heart Association; 1994.
- Pearson T, Rapaport E, Criqui M, et al. Optimal risk factor management in the patient after coronary revascularization. *Circulation* 1994;90:3125-3133.
- Pearson TA, McBride PE, Houston-Miller N, Smith SC. Task Force 8. Organization of preventive cardiology service. *J Am Coll Cardiol* 1996;27:1039-1047.
- Pedersen TR, Kjekshus J, Berg K, et al. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). *Lancet* 1994;344:1383-1389.
- Pekkanen J, Linn S, Heiss G, et al. Ten-year mortality from cardiovascular disease in relation to cholesterol level among men with and without preexisting cardiovascular disease. *N Engl J Med* 1990;322:1700-1707.
- Pfeffer MA, Braunwald E, Moya LA, et al. Effect of Captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. *N Engl J Med* 1992;327: 669-677.
- Reis S, Gloth S, Blumenthal R, et al. Ethinyl estradiol acutely attenuates abnormal coronary vasomotor responses to acetylcholine in postmenopausal women. *Circulation* 1994;89:52-60.
- Rutherford JD, Pfeffer MA, Moya LA, et al. Effects of captopril on ischemic events after myocardial infarction. *Circulation* 1994;90:1731-1738.
- Sacks FM, Pasternak RC, Gibson CM, Rosner B, Stone PH. The Harvard Atherosclerosis Reversibility Project (HARP) group: Effect on coronary atherosclerosis of decrease in plasma cholesterol concentrations in normocholesterolemic patients. *Lancet* 1994;344:1182-1186.
- Sacks FM, Pfeffer MA, Moya LA, et al, and the Cholesterol and Recurrent Events (CARE) Trial Investigators. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. *N Engl J Med* 1996;335:1001-1009.
- Shepherd J, Cobbe S, Ford I, et al, for the West of Scotland Coronary Prevention Study (WOSCOPS) Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. *N Engl J Med* 1995;333:1301-1307.
- Smith P, Arnesen H, Holme I. The effect of warfarin on mortality and reinfarction after myocardial infarction. *N Engl J Med* 1990;323:147-152.
- Smith SC. Risk reduction therapy: The challenge to change. *Circulation* 1996;93:2205-2211.
- Smith SC, Blair SN, Criqui MH, et al. Preventing heart attack and death in patients with coronary disease. *Circulation* 1995;92:2-4.
- US Department of Health and Human Services. *Cardiac Rehabilitation Clinical Practice Guideline Number 17*. AHCPR Publication No 96-0672. 1995.
- Williams J, Adams M, Klopfenstein H. Estrogen modulates responses of atherosclerotic coronary arteries. *Circulation* 1990;81:1680-1687.
- Wirebaugh SR, Whitney EJ. Long-term compliance with lipid-lowering therapy. *Pharmacotherapy* 1993;18:559-571.
- The Writing Group for the PEPI Trial: Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women: The Postmenopausal Estrogen/Progestin Interventions (PEPI) trial. *JAMA* 1995;273:199-208.
- Yusuf S, Pepine CJ, Gances C, et al. The effect of enalapril on myocardial infarction and unstable angina in patients with low ejection fractions. *Lancet* 1992;340:1173-1178.
- Yusuf S, Peto J, Lewis J, Collins R, Sleight P. Beta blockade during and after myocardial infarction: An overview of the randomized trials. *Prog Cardiovasc Dis* 1985;27:335-371.